IntelGenx Technologies Corp. Appoints New Vice President of Business Development

August 07, 2007

SAINT LAURENT, QUEBEC--(CCNMatthews - Aug. 7, 2007) - IntelGenx Technologies Corp. (OTCBB:IGXT), a drug delivery company creating new delivery technologies for generic pharmaceutical markets, announced today the appointment of James Wittenberg, R.Ph., M.S., as the Company's Vice President of Business Development, effective immediately.

Mr. Wittenberg has over 20 years of experience providing market research and business development to pharmaceutical companies. Most recently he served as Director of Business Development at Schwarz Pharma. Earlier he was a Manager of Market Research at Boots Pharmaceuticals and led the market research support for the launch of Manoplex. He is a Registered Pharmacist and received his Bachelor's and Master's degrees in Pharmacy from the University of Wisconsin.

Horst G. Zerbe, President and CEO, IntelGenx, said, "We are very pleased to have Jim join the management team of IntelGenx. His strong business development background will help us bring to market our diversified pipeline of drug delivery products to enhance the treatment of conditions including osteoarthritis, pain management, hypertension and smoking cessation, among others. We believe he will contribute importantly to our business strategy and growth."

Mr. Wittenberg stated, "I'm delighted to work with the creative management of IntelGenx to help advance their marketing and licensing plans and relations with strategic pharmaceutical partners in the U.S. and abroad. IntelGenx's unique technologies and extensive product pipeline address multi-billion-dollar markets. I look forward to helping expand their plans for commercialization."

About IntelGenx Technologies

IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company's research and development pipeline includes products for the treatment of osteoarthritis, pain management, hypertension and smoking cessation. Since January 2007, IntelGenx has been trading on the OTCBB. To learn more about IntelGenx, please visit the Company's website at http://www.intelgenx.com.

Forward-Looking Statements

Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Pursuant to a June 1, 2007 contract, Consulting For Strategic Growth1, Ltd. ("CFSG1") provides IntelGenx Corp. ("the Company") with consulting, business advisory, investor relations, public relations and corporate development services. Independent of CFSG1's receipt of cash compensation from the Company, CFSG1 may choose to purchase the Company's common stock and thereafter liquidate those securities at any time it deems appropriate to do so.

FOR FURTHER INFORMATION PLEASE CONTACT:

IntelGenx Corp.
Dr. Horst G. Zerbe
President and CEO
(514) 331-7440, Ext. 201
(514) 331-0436 (FAX)
Email: horst@IntelGenx.com
Website: www.intelgenx.com


Investor Relations:
Consulting for Strategic Growth 1
Stanley Wunderlich, CEO
Toll Free: 1-800-625-2236
(212) 337-8089 (FAX)

Email: info@cfsg1.com


Media Relations:
Consulting for Strategic Growth 1
Daniel Stepanek
(212) 896-1202
(212) 697-0910 (FAX)
Email: dstepanek@cfsg1.com
Website: www.cfsg1.com

Source: CCN Matthews (August 7, 2007 - 9:23 AM EST)

News by QuoteMedia
www.quotemedia.com